Amorphous Selenium Imaging for Tomotherapy

用于断层放射治疗的非晶硒成像

• 批准号: 6786033
• 负责人: GUANG M FANG
• 金额: $ 40.49万
• 依托单位: TOMOTHERAPY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-05 至 2006-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6786033
• 关键词: amorphous solid; bioimaging /biomedical imaging; biomedical equipment development; high throughput technology; image enhancement; image guided surgery /therapy; model design /development; neoplasm /cancer radiation therapy; quantum chemistry; radiation detector; radiation dosage; radiation sensitivity; selenium; statistics /biometry; tomography

DESCRIPTION (provided by applicant): TomoTherapy Incorporated was founded in 1997 to develop and commercialize a new type of radiation therapy device for improving cancer treatment. TomoTherapy's first FDA cleared product, the HiArt System, combines, for the first time, the means to accurately plan, deliver, verify and review treatments for cancer therapy, and as a result, to greatly improve treatment results and lifestyles of cancer patients because of the better targeting of irradiation to the tumor and the sparing of normal tissue. This "entire radiotherapy department in a machine" integration and automation greatly reduces the need for human intervention, thus reducing staff needs for cancer treatment. The HiArt System employs image-guided radiation delivery, enabling tumors to be irradiated more effectively while saving the critical organs surrounding the tumor. Central to the capability of image-guided radiotherapy is a detector system that efficiently detects high energy x-rays employed in cancer therapy. The objective of the proposed project is to develop a new type of megavoltage detector system that meets all the requirements of tomotherapy imaging applications. The proposed design combines i) amorphous selenium (a-Se) material which has seen extensive research and development in applications ranging from imaging and display, to radiology and astronomy, with ii) TomoTherapy's patented technology for improving detection efficiency for high energy x-rays. This new detector system will improve the detection efficiency, a key requirement for an imaging detector, over the existent technology by an order of magnitude, thus offering great improvement in resolving power on the images. When employed, the multi-row approach and the improved detection efficiency and readout speed of the new detector will improve the tomotherapy imaging quality and throughput significantly, and offers great potential for imaging the patient in real-time during treatment, a key element for further improving cancer treatment where organ motion is a significant obstacle to improved precision. It is expected that the proposed detector will also save $10 to $20 million in tomotherapy manufacturing cost yearly. This technology also has potential applications in other areas as well, including security inspections at ports, forest inspections and orthopedic imaging where there are implanted metal devices or joints.

描述（由申请人提供）： TomoTherapy Incorporated成立于1997年，旨在开发和商业化一种新型放射治疗设备，以改善癌症治疗。TomoTherapy的第一个FDA批准的产品HiArt系统首次结合了准确计划、交付、验证和审查癌症治疗的方法，因此，由于更好地将辐射靶向肿瘤并保留正常组织，极大地改善了治疗结果和癌症患者的生活方式。这种“整个放疗科在一台机器上”的集成和自动化大大减少了对人工干预的需求，从而减少了癌症治疗的人员需求。 HiArt系统采用图像引导放射输送，使肿瘤能够更有效地照射，同时挽救肿瘤周围的关键器官。图像引导放射疗法的能力的核心是有效检测癌症治疗中采用的高能X射线的检测器系统。拟议项目的目标是开发一种新型的兆伏探测器系统，满足断层治疗成像应用的所有要求。所提出的设计结合了i）非晶硒（a-Se）材料，该材料在成像和显示，放射学和天文学等应用领域进行了广泛的研究和开发，ii）TomoTherapy的专利技术，用于提高高能X射线的检测效率。这种新的探测器系统将提高探测效率，这是成像探测器的关键要求，超过现有技术一个数量级，从而在图像上提供了很大的提高分辨率。当采用时，多行方法以及新探测器的改进的探测效率和读出速度将显著提高断层治疗成像质量和通量，并为在治疗期间实时成像患者提供巨大潜力，这是进一步改善癌症治疗的关键要素，其中器官运动是提高精度的重要障碍。预计所提出的探测器每年还将节省1000万至2000万美元的断层治疗制造成本。这项技术在其他领域也有潜在的应用，包括港口的安全检查，森林检查和植入金属设备或关节的整形外科成像。